4.5 Article

Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis

Journal

NEUROBIOLOGY OF AGING
Volume 36, Issue 1, Pages 492-504

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2014.06.026

Keywords

ALS; SOD1G93A transgenic mouse; Protein quality control; Chaperone; Alpha-B-crystallin; Cyclophillin-A; Proteasome; Autophagy

Funding

  1. Motor Neurone Disease Association, UK [124695-1]
  2. European Community's Seventh Framework Programme (FP7) [259867]
  3. National Institute of Health Research Senior Investigator
  4. Fondazione Telethon Funding Source: Custom
  5. National Institute for Health Research [NF-SI-0512-10082] Funding Source: researchfish

Ask authors/readers for more resources

Amyotrophic lateral sclerosis (ALS) is a disease of variable severity in terms of speed of progression of the disease course. We found a similar variability in disease onset and progression of 2 familial ALS mouse strains, despite the fact that they carry the same transgene copy number and express the same amount of mutant SOD1G93A messenger RNA and protein in the central nervous system. Comparative analysis of 2 SOD1G93A mouse strains highlights differences associated with the disease severity that are unrelated to the degree of motor neuron loss but that appear to promote early dysfunction of these cells linked to protein aggregation. Features of fast progressing phenotype are (1) abundant protein aggregates containing mutant SOD1 and multiple chaperones; (2) low basal expression of the chaperone alpha-B- crystallin (CRYAB) and beta 5 subunits of proteasome; and (3) downregulation of proteasome subunit expression at disease onset. In contrast, high levels of functional chaperones such as cyclophillin-A and CRYAB, combined with delayed alteration of expression of proteasome subunits and the sequestration of TDP43 into aggregates, are features associated with a more slowly progressing pathology. These data support the hypothesis that impairment of protein homeostasis caused by low-soluble chaperone levels, together with malfunction of the proteasome degradation machinery, contributes to accelerate motor neuron dysfunction and progression of disease symptoms. Therefore, modulating the activity of these systems could represent a rational therapeutic strategy for slowing down disease progression in SOD1-related ALS. (C) 2015 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available